How to take Temsirolimus

The recommended dose of Temsirolimus for the treatment of advanced renal cell carcinoma (RCC) is 25 mg as an intravenous infusion once a week for 30-60 minutes each time. Treatment should be continued until disease progression or unacceptable toxicity occurs. The recommended dose for the treatment of mantle cell lymphoma (MCL) is 175 mg as an intravenous infusion once a week for 30-60 minutes for 3 weeks, followed by a dose reduction to 75 mg once a week for 30-60 minutes. Treatment should be continued until disease progression or unacceptable toxicity occurs.

Patients should receive a prophylactic intravenous injection of diphenhydramine 25-50 mg (or a similar antihistamine) approximately 30 minutes before each dose of temsirolimus. Temsirolimus should be retained for adverse reactions with absolute neutrophil count (ANC) <1000/mm3, platelet count <75000/mm3, or NCI CT CAE grade 3 or higher. Once toxicity drops to grade 2 or less, temsirolimus can be restarted with a dose reduction of 5 mg/week to no less than 15 mg/week. If temsirolimus must be administered to patients with mild hepatic impairment (bilirubin >1-1.5 × ULN or AST >ULN but bilirubin ≤ ULN), reduce the dose to 15 mg/week. Temsirolimus is contraindicated in patients with bilirubin >1.5×ULN.Temsirolimus is contraindicated.

The original drug temsirolimus has not yet been marketed in China, and therefore cannot be included in domestic medical insurance. The original temsirolimus drug marketed overseas has a Turkish version and a European version. The ingredients of the two are basically the same. The price of each box of 30mg/1.2mL may be more than 10,000 yuan, and the price of 25mg/mL may be around 3,000 yuan per box (the price may fluctuate due to exchange rates). There is currently no generic version of temsirolimus available on the market. For more drug information and specific prices, please consult a medical consultant.